Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 772 across all filing types
Latest filing 2026-02-03 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Action(s) initiated or orders passed
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI Listing Regulations, reporting a GST authority visit and inspection at the company's registered office. It includes details of the inspection authorization and compliance with disclosure requirements. The document is addressed to stock exchanges and is a regulatory announcement about an ongoing inspection, not a financial report, earnings release, or management discussion. It is short (2881 characters) and serves as a regulatory disclosure of an event affecting the company. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-03 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) reporting the allotment of equity shares under an Employee Stock Option Plan (ESOP). It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details of the share allotment, including the increase in paid-up capital. The document is an announcement of a capital change event (allotment of shares under ESOP), not a full financial report or earnings release. It is relatively short (3166 characters) and focuses on the issuance of shares, which fits the category of Share Issue/Capital Change (SHA).
2026-02-03 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) pursuant to Regulation 30 of SEBI Listing Regulations, which governs continuous disclosures by listed companies. The content announces the final approval of the company's Abbreviated New Drug Application (ANDA) by the USFDA for a pharmaceutical product. It includes a press release with details about the product, manufacturing, and company background. The document is relatively short (4471 characters) and primarily serves as an announcement of a significant corporate event rather than a detailed financial or operational report. There are no financial statements, management discussion, or detailed analysis present. This fits the profile of a Regulatory Filing (RNS) as it is a regulatory disclosure about a material event but not a financial report or other specific filing type. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-01-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a notification to stock exchanges about an upcoming earnings conference call for the quarter and nine months ended 31st December 2025. It includes details about the call schedule, participants, and dial-in information. The document does not contain actual financial results or detailed financial statements but serves as an announcement of the conference call event. The document length is 3827 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript announcement (CT) or more precisely an announcement of the earnings call. However, since it is only an intimation of the earnings conference call and not the transcript itself, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call event. Confidence is high due to clear references to the earnings call and regulatory citation (SEBI LODR).
2026-01-20 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-16 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying about an upcoming Board Meeting scheduled to consider and approve the company's un-audited financial results for the quarter and nine months ended December 31, 2025. It references compliance with SEBI regulations and mentions the closure of the trading window around the announcement date. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is an announcement of a Board Meeting and related procedural information, not the actual financial report or earnings release. Therefore, it fits best under Board/Management Information (MANG), as it relates to board meeting scheduling and regulatory compliance notifications.
2026-01-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.